安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选

环球市场播报07-14

安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局（FDA）的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。　　此次获批是基于该试剂盒在多个临床试验中展现出的准确识别适合接受特定免疫疗法的患者的能力。对于上述癌症类型，PD-L1...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2651104260?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-14 22:38","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2651104260","market":"sg","top_or_hot":-1,"title":"安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选","media":"环球市场播报","content":"<div>\n<p>安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局（FDA）的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。\n　　此次获批是基于该试剂盒在多个临床试验中展现出的准确识别适合接受特定免疫疗法的患者的能力。对于上述癌症类型，PD-L1...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-14 22:38 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局（FDA）的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。\n　　此次获批是基于该试剂盒在多个临床试验中展现出的准确识别适合接受特定免疫疗法的患者的能力。对于上述癌症类型，PD-L1...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml","article_id":"2651104260","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651104260","pubTimestamp":1784039880,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。　　安捷伦表示，此次获批有助于标准化相关癌症的免疫治疗患者筛选流程，支持全球临床医生做出更精准的治疗决策。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4023":"应用软件","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","PD":"PagerDuty, Inc.","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股"},"translate_title":"Agilent PD-L1 concomitant diagnostic reagent approved by FDA for esophageal and gastric cancer immunotherapy screening","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1.5,"LABU":1.5},"content_text":"安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局（FDA）的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。\n　　此次获批是基于该试剂盒在多个临床试验中展现出的准确识别适合接受特定免疫疗法的患者的能力。对于上述癌症类型，PD-L1表达水平是医生判断患者能否从免疫治疗中获益的关键生物标志物之一。安捷伦的伴随诊断试剂盒能够为病理实验室提供一种标准化、经过临床验证的工具，用以量化肿瘤组织样本中的PD-L1表达水平。\n　　该试剂盒是安捷伦在肿瘤诊断领域的重要产品之一。其核心优势在于为全球的病理实验室提供了统一、可靠的检测标准，有助于确保不同地区、不同实验室的检测结果具有可比性，从而支持临床医生为患者制定更精准的治疗方案。此前的数据表明，该检测方法在肺癌、黑色素瘤等多种实体瘤中均有应用，且在分析灵敏度和特异性方面表现出较高的重复性。\n　　安捷伦表示，此次获批有助于标准化相关癌症的免疫治疗患者筛选流程，支持全球临床医生做出更精准的治疗决策。公司还称，PD-L1 IHC 28-8 pharmDx试剂盒已可在美国市场订购。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651104260","isCrawlerRequest":true}